ClinicalTrials.gg

Program

peginterferon alfa-2a

Also written as “peginterferon alfa-2a [Pegasys]”, “Peginterferon alfa-2a” and “Pegylated Interferon Alfa-2a”.

Its studies are mostly in Hepatitis C, Chronic · Hepatitis B, Chronic · Hepatitis C · Hepatitis D, Chronic · Leukemia, Myelogenous, Chronic, BCR-ABL Positive, led by 6 companies.

Furthest: phase 4, since Feb 10, 200483 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche670 open or runningphase 4since Feb 10, 2004Nov 12, 2002none ahead
Vertex Pharmaceuticals80 open or runningphase 4since Nov 3, 2011Jul 27, 2004none ahead
Johnson & Johnson50 open or runningphase 3since Dec 6, 2011Dec 6, 2011none ahead
getz-pharma10 open or runningphase 4since Nov 2, 2015Nov 2, 2015none ahead
janssen-infectious-diseases-bvba10 open or runningphase 3since Oct 28, 2010Oct 28, 2010none ahead
Nanogen Pharmaceutical Biotechnology Joint Stock10 open or runningphase 4since Apr 3, 2025Apr 3, 2025none ahead

Also a collaborator on its studies: Dimension Research, CPR Pharma Services Pty Ltd, Australia, Roche Pharma, ViroChem Pharma and Tibotec Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since May 16, 2007.

  1. Oct 8, 2015Phase 1 study in Healthy VolunteersHoffmann-La Roche · NCT02573025 · 277 enrolled · Australia, Hong Kong, New Zealand and more
  2. Oct 14, 2015Phase 2 study in Carcinoma, HepatocellularHoffmann-La Roche · NCT02576964 · 16 enrolled · China, Taiwan, Thailand
  3. Nov 2, 2015getz-pharma’s first study: phase 4 study in Hepatitis CNew to getz-pharmagetz-pharma · NCT02601976 · 64 enrolled
  4. Nov 4, 20152 phase 4 studies in Hepatitis B, ChronicHoffmann-La Roche · NCT02604823, NCT02598063
  5. Dec 11, 2015Phase 4 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02641379 · 737 enrolled · Austria
  6. Mar 18, 2016Phase 2 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02716779 · 68 enrolled · Germany
  7. Apr 1, 2016Phase 2 study in Hepatitis D, ChronicHoffmann-La Roche · NCT02731131 · 12 enrolled · Italy
  8. Apr 5, 20162 phase 3 studiesHoffmann-La Roche · NCT02732639, NCT02736721
  9. May 3, 20162 phase 3 studiesHoffmann-La Roche · NCT02762383, NCT02791256
  10. May 31, 2016Phase 4 study in Hepatitis B, ChronicHoffmann-La Roche · NCT02791269 · 24 enrolled · New Zealand
  11. Jun 16, 2016Phase 3 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02806505 · 81 enrolled · Austria, Brazil, France and more
  12. Jul 6, 2016Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveHoffmann-La Roche · NCT02829775 · 9 enrolled · Bulgaria, Canada, India and more
  13. Aug 9, 2016Phase 4 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02864199 · 63 enrolled · United States, Brazil, France and more
  14. Apr 3, 2025Nanogen Pharmaceutical Biotechnology Joint Stock’s first study: phase 4 study in Hepatitis C, ChronicNew to Nanogen Pharmaceutical Biotechnology Joint StockNanogen Pharmaceutical Biotechnology Joint Stock · NCT06922643 · 100 enrolled

TargetBeta

“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Interferon beta-1aruleBiogenphase 460
peginterferon alfa-2bruleMerckphase 456

Studies

The newest 60 of 83 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06922643Hepatitis C, Chronic4CompletedNanogen Pharmaceutical Biotechnology Joint StockJan 21, 2013100
NCT02864199Hepatitis C, Chronic · United States, Brazil, France and more4CompletedHoffmann-La RocheSep 200763
NCT02829775Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Bulgaria, Canada, India and more3CompletedHoffmann-La RocheJan 20089
NCT02806505Hepatitis C, Chronic · Austria, Brazil, France and more3CompletedHoffmann-La RocheAug 200781
NCT02791269Hepatitis B, Chronic · New Zealand4CompletedHoffmann-La RocheJul 200824
NCT02791256Hepatitis C, Chronic · Belgium3TerminatedHoffmann-La RocheJun 200823
NCT02762383HIV/HCV Coinfection · Belgium3TerminatedHoffmann-La RocheJun 200919
NCT02736721Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany3CompletedHoffmann-La RocheNov 201041
NCT02732639Hepatitis D, Chronic · Romania3CompletedHoffmann-La RocheDec 200831
NCT02731131Hepatitis D, Chronic · Italy2CompletedHoffmann-La RocheMay 200912
NCT02716779Hepatitis C, Chronic · Germany2CompletedHoffmann-La RocheApr 201068
NCT02641379Hepatitis C, Chronic · Austria4CompletedHoffmann-La RocheNov 2013737
NCT02604823Hepatitis B, Chronic · China4CompletedHoffmann-La RocheNov 2005307
NCT02598063Hepatitis B, Chronic · China, Hong Kong4CompletedHoffmann-La RocheApr 2009255
NCT02601976Hepatitis C4Completedgetz-pharmaSep 201264
NCT02576964Carcinoma, Hepatocellular · China, Taiwan, Thailand2CompletedHoffmann-La RocheNov 200816
NCT02573025Healthy Volunteers · Australia, Hong Kong, New Zealand and more1CompletedHoffmann-La RocheApr 11, 2016277
NCT02570191Hepatitis B, Chronic · Bulgaria4CompletedHoffmann-La RocheFeb 200760
NCT02401737Hepatitis B, Chronic · United States, China, Korea, Republic of and more1CompletedJohnson & JohnsonMay 18, 201658
NCT02263079Pediatric Immuno-Tolerant Chronic Hepatitis B · United States, Australia, Belgium and more3CompletedHoffmann-La RocheJan 29, 202062
NCT02112799Hepatitis B, Chronic · New Zealand1CompletedJohnson & JohnsonMay 18, 201655
NCT01853254Hepatitis C, Chronic · United States, Australia, Brazil and more3CompletedHoffmann-La RocheSep 2011272
NCT01787279Hepatitis B, Chronic · Morocco4CompletedHoffmann-La RocheMay 200959
NCT01749150Hepatitis C, Chronic · Korea, Republic of, Taiwan, Thailand2CompletedHoffmann-La RocheFeb 201561
NCT01706575Hepatitis B, Chronic · Italy2CompletedHoffmann-La RocheSep 201376
NCT01591460Hepatitis C, Chronic · Austria, Germany, Hungary and more4CompletedHoffmann-La RocheJun 2014165
NCT01585324Hepatitis C, Chronic · Czech Republic4CompletedHoffmann-La RocheJan 201430
NCT01513941Hepatitis C, Chronic · Australia, Brazil, France and more3CompletedJohnson & JohnsonMar 2014163
NCT01519921Hepatitis B, Chronic · Korea, Republic of4CompletedHoffmann-La RocheJun 2008150
NCT01571583Hepatitis C, Chronic · Austria, Belgium, France and more3CompletedJohnson & JohnsonApr 201474
NCT01519960Hepatitis B, Chronic · United States, Australia, Belgium and more3CompletedHoffmann-La RocheJul 9, 2015165
NCT01498068Hepatitis C · Russian Federation3CompletedJohnson & JohnsonApr 201236
NCT01467505Hepatitis C · United States, Canada2TerminatedVertex PharmaceuticalsApr 201461
NCT01467492Hepatitis C · United States4TerminatedVertex PharmaceuticalsMay 2014121
NCT01467479Hepatitis C · United States, Canada, Germany and more3TerminatedVertex PharmaceuticalsFeb 2014185
NCT01459913Hepatitis C, Chronic · United States, Austria, Canada and more3TerminatedVertex PharmaceuticalsJan 2014239
NCT01447420Hepatitis C, Chronic · Brazil4CompletedHoffmann-La RocheNov 2012129
NCT01429792Hepatitis C, Chronic · Israel4CompletedHoffmann-La RocheJun 10, 20131,013
NCT01337375Hepatitis C, Chronic · Germany1CompletedHoffmann-La RocheApr 201231
NCT01278134Hepatitis C, Chronic · United States, France, Germany and more2CompletedHoffmann-La RocheOct 2012170
NCT01296971Hepatitis C, Chronic3WithdrawnHoffmann-La RocheDec 20090
NCT01258101Hepatitis C, Chronic · Austria4CompletedHoffmann-La RocheJul 2008395
NCT01237496Hepatitis B, Chronic · Italy3CompletedHoffmann-La RocheSep 200917
NCT01241760Hepatitis C · United States, Australia, Austria and more3Completedjanssen-infectious-diseases-bvbaAug 2012744
NCT01095835Hepatitis B, Chronic · Italy3CompletedHoffmann-La RocheJan 2010131
NCT01086085Hepatitis B, Chronic · China4CompletedHoffmann-La RocheMar 2013265
NCT01033448Hepatitis C, Chronic · Israel4CompletedHoffmann-La RocheJun 201359
NCT00983853Hepatitis C · United States, France, Germany and more2CompletedVertex PharmaceuticalsMar 201262
NCT00962975Hepatitis B, Chronic · United States, New Zealand, Singapore and more1CompletedHoffmann-La RocheMay 201329
NCT00962871Hepatitis B, Chronic · United States, New Zealand, Singapore and more1CompletedHoffmann-La RocheFeb 201230
NCT00940485Hepatitis B, Chronic · China4CompletedHoffmann-La RocheDec 2011200
NCT00927082Hepatitis B, Chronic · Australia, Brazil, China and more4CompletedHoffmann-La RocheNov 2014383
NCT00922779Hepatitis C, Chronic · Russian Federation4CompletedHoffmann-La RocheJun 20126,661
NCT00911963Hepatitis C · United States, Argentina, Canada and more2CompletedVertex PharmaceuticalsSep 201249
NCT00800748Hepatitis C, Chronic · Czechia, Slovakia4CompletedHoffmann-La RocheJan 9, 2009372
NCT00800735Hepatitis C, Chronic · United States, Austria, Canada and more3CompletedHoffmann-La RocheMar 201230
NCT00623428Hepatitis C, Chronic · United States, Australia, Austria and more3CompletedHoffmann-La RocheMay 2012235
NCT00487747Hepatitis B, Chronic · Russian Federation4CompletedHoffmann-La RocheOct 200918
NCT00483938Hepatitis C, Chronic · United States, Canada3CompletedHoffmann-La RocheMay 2010236
NCT00475072Hepatitis C, Chronic · Mexico4CompletedHoffmann-La RocheJul 200614

How it is read

Names in the registry

  • “peginterferon alfa-2a [Pegasys]”, 38 entries
  • “Peginterferon alfa-2a”, 21 entries
  • “peginterferon alfa-2a”, 9 entries
  • “Pegylated Interferon Alfa-2a”, 5 entries
  • “peginterferon alfa-2a [PEGASYS]”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
peginterferon alfa-2a (Hoffmann-La Roche): development program | ClinicalTrials.gg